PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Annals of Epidemiology10.1016/j.annepidem.2012.06.0152012229663Androgen Deprivation Therapy for Treatment of Localized Prostate Cancer and Risk of Second Primary MalignanciesL.P. Wallner, R. Wang, S.J. Jacobsen, R. Haquehttps://api.elsevier.com/content/article/PII:S1047279712002049?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1047279712002049?httpAccept=text/plain
Cancer10.1002/cncr.258172010117112577-2578Reply to comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancerMatthew R. Cooperberg, Peter R. Carroll, Andrew J. Vickershttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.25817
Cancer10.1002/cncr.259492011117153532-3532Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancerAxel Madlung, Mathew Simcock, Pirus Ghadjarhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.25949
Cancer10.1002/cncr.259472011117153532-3533Reply to comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancerMatthew R. Cooperberg, Andrew J. Vickers, Peter R. Carrollhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.25947
Cancer10.1002/cncr.258192010117112577-2577Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancerMichael Froehnerhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.25819, https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.25819
Clinical Endocrinology10.1111/j.1365-2265.2010.03939.x2011743289-293Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?Mathis Grossmann, Jeffrey D. Zajachttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2265.2010.03939.x
Clinical Prostate Cancer10.1016/s1540-0352(11)70015-420032122-23Androgen-Deprivation Therapy for Prostate CancerCelestia Higanohttps://api.elsevier.com/content/article/PII:S1540035211700154?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1540035211700154?httpAccept=text/plain
Value in Health10.1016/j.jval.2011.02.9742011143A176PCN120 WHO CHOSE PRIMARY ANDROGEN DEPRIVATION THERAPY OVER RADICAL PROSTATECTOMY: A RETROSPECTIVE STUDY AMONG VETERANS WITH LOCALIZED PROSTATE CANCERJ. Liu, L. Shi, O. Sartorhttps://api.elsevier.com/content/article/PII:S1098301511011132?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301511011132?httpAccept=text/plain
Hormone Therapy and Castration Resistance of Prostate Cancer10.1007/978-981-10-7013-6_142018121-131Androgen Deprivation Therapy for Clinically Localized Prostate CancerYoichi Arai, Koji Mitsuzukahttp://link.springer.com/content/pdf/10.1007/978-981-10-7013-6_14
Yearbook of Oncology10.1016/s1040-1741(08)79269-82009200961-63Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate CancerC.A. Lawtonhttps://api.elsevier.com/content/article/PII:S1040174108792698?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1040174108792698?httpAccept=text/plain